Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Eduardo Fernandez MD, PhD

Advertisement

Articles by Eduardo Fernandez MD, PhD

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

ByGustavo Olivera PhD,Xiaohu Mo MS,Don Parnell CMD,Stephanie Key CMD,Constantine Mantz, MD,Eduardo Fernandez MD, PhD,Daniel Dosoretz MD,Arie Dosoretz MD,Larry Kestin MD,Alvaro Martinez, MD,Steven E. Finkelstein, MD
June 13th 2015

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Advertisement

Latest Updated Articles

  • Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation
    Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

    June 13th 2015



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

2

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma

3

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

4

VIR-5500 Receives FDA Fast Track Designation in mCRPC

5

FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us